At CRU Hungary we have developed an alternative approach to the STEP61 inhibition problem. Based on an early proof-of-concept we are now able to develop molecules that can specifically inhibit STEP61 activity without affecting other vital proteins, like the PTPs. Hence, we will provide a set of cognitive-enhancing compounds focused in the treatment of dementia that will provide both efficacy and specificity, avoiding severe and life-endangering side effects. Through the DEM-AID project we will generate a portfolio of validated preclinical leads. These leads will be further developed through the different clinical stages in collaboration con academic and pharmaceutical partners, to finally obtain an effective treatment for dementia that will decrease the huge social and economic burden.